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Chronic myelogenous leukemia (CML) is caused
by the constitutively active tyrosine kinase Bcr-Abl
and treated with the tyrosine kinase inhibitor (TKI)
imatinib. However, emerging TKI resistance prevents
complete cure. Therefore, alternative strategies tar-
geting regulatory modules of Bcr-Abl in addition to
the kinase active site are strongly desirable. Here,
we show that an intramolecular interaction between
the SH2 and kinase domains in Bcr-Abl is both
necessary and sufficient for high catalytic activity
of the enzyme. Disruption of this interface led to
inhibition of downstream events critical for CML
signaling and, importantly, completely abolished
leukemia formation in mice. Furthermore, disruption
of the SH2-kinase interface increased sensitivity
of imatinib-resistant Bcr-Abl mutants to TKI inhibi-
tion. An engineered Abl SH2-binding fibronectin
type III monobody inhibited Bcr-Abl kinase activity
both in vitro and in primary CML cells, where it in-
duced apoptosis. This work validates the SH2-kinase
interface as an allosteric target for therapeutic
intervention.
INTRODUCTION
The deregulated, constitutively activated tyrosine kinase Bcr-Abl
is expressed from the Philadelphia chromosome after the t(9;22)
chromosomal translocation that leads to the fusion of the
breakpoint cluster region (BCR) gene and the Abelson tyrosine306 Cell 147, 306–319, October 14, 2011 ª2011 Elsevier Inc.kinase (ABL1) (Wong and Witte, 2004). The defining molecular
event of chronic myelogenous leukemia (CML) in humans is the
expression of Bcr-Abl, which is sufficient for the initiation and
maintenance of CML-like disease in mouse models (Daley
et al., 1990). Bcr-Abl activates a large number of signaling
pathways that lead to uncontrolled proliferation, inhibition of
apoptosis, and block of myeloid differentiation. Many of these
pathways are thought to act in a redundant fashion, as only
a few signaling components have thus been reported to be
critical for Bcr-Abl-mediated oncogenic transformation. These
included the transcription factors STAT5 and Myc, as well as
the adaptor protein Gab2 (Nieborowska-Skorska et al., 1999;
Hoelbl et al., 2010; Sattler et al., 2002).
Inhibition of Bcr-Abl tyrosine kinase activity by the highly
specific Bcr-Abl inhibitor imatinib (Gleevec) leads to durable
cytogenetic and molecular remissions in the majority of CML
patients in the early chronic phase of the disease and is supe-
rior to previous therapies in advanced stage CML (Hochhaus
et al., 2009; Deininger et al., 2005). The occurrence of imatinib
resistance—mainly caused by point mutations in the Bcr-Abl
kinase domain—leads to patient relapse, bears the risk of
disease progression, and resulted in the development and
rapid approval of the second-generation inhibitors nilotinib
and dasatinib that target most imatinib-resistant Bcr-Abl vari-
ants (Shah and Sawyers, 2003; Quinta´s-Cardama et al.,
2007). However, unsatisfactory responses in advanced disease
stages, resistance, and problematic long-term tolerability of all
three Bcr-Abl inhibitors remain major clinical problems (Jab-
bour et al., 2010). All approaches aimed at targeting the ATP-
binding pocket of the Bcr-Abl kinase domain alone do not
target the disease-initiating leukemic stem cells, and thus,
patients are not cured from CML (Perrotti et al., 2010). Combi-
nation therapy of imatinib with drugs that target downstream
signaling components of Bcr-Abl yielded promising results in
preclinical studies (reviewed in Deininger et al., 2005). Still,
these approaches have currently not been followed up further,
as restoration of Bcr-Abl activity by resistance mutations
appears to be dominant and override additive or synergistic
inhibitory effects of the second drug (Deininger et al., 2005).
For these reasons, approaches to target additional sites on
Bcr-Abl itself in combination with the commonly targeted
ATP-binding pocket may result in superior future therapeutic
options.
Studies on the structure and dynamics of c-Abl/Bcr-Abl regu-
lation have identified key regulatory mechanisms (reviewed in
Hantschel and Superti-Furga, 2004). Binding of the N-terminal
myristate moiety to a unique binding pocket in the c-Abl kinase
domain was found to be critical for autoinhibition (Hantschel
et al., 2003, Nagar et al., 2003). The myristate pocket was tar-
geted by the non-ATP-competitive compound GNF-2/GNF-5
that led to inhibition of pan-TKI resistant Bcr-Abl variant T315I
in a mouse model in combination with nilotinib (Zhang et al.,
2010).
SH2 domains constitute one of the largest families of eu-
karyotic protein-protein interaction domains and bind phos-
photyrosine moieties with a certain sequence specificity
(Pawson et al., 2001). Aside from their well-described role in
mediating intermolecular protein interactions, the SH2 domains
in certain cytoplasmic tyrosine kinases, like c-Abl and Fes,
were shown to activate the adjacent tyrosine kinase domain
(Filippakopoulos et al., 2008). The ability of the Abl SH2
to stimulate kinase activity was dependent on the establish-
ment of a tight interface between the SH2 domain and the
N-terminal lobe of the kinase domain (Filippakopoulos et al.,
2008; Nagar et al., 2006). Mutations in the SH2 domain that
disrupt this SH2-kinase domain interface resulted in severe
impairment of kinase activity. Thus, correct positioning of the
SH2 and kinase domain modules appears to be critical for
efficient activation of cytoplasmic tyrosine kinases (Filippako-
poulos et al., 2008).
In the oncogenic fusion Bcr-Abl, the Bcr moiety contains
important regulatory elements that contribute to constitutive
activation and cellular transformation. The Grb2 docking site
(Tyr177 in Bcr) and the coiled-coil oligomerization domain were
shown to support Bcr-Abl leukemogenicity (McWhirter et al.,
1993; Million and Van Etten, 2000). Therefore, whether or not
SH2-mediated allosteric activation of the kinase domain is
operable on the already highly activated Bcr-Abl fusion kinase
or even affects its leukemogenicity were entirely unclear. There-
fore, we set out to understand the functional role of the SH2-
kinase domain interface in the context of Bcr-Abl.
The data presented here show that the SH2-kinase domain
interface is critical for Bcr-Abl activity both in vitro and in cells.
Disruption of this interface abolished the development of CML
in a mouse bone marrow transplantation model and enhanced
TKI sensitivity of nonmutated and TKI-resistant Bcr-Abl forms.
Finally, an engineered high-affinity Abl SH2 domain-binding
protein targeted to the SH2-kinase interface was found to
strongly inhibit Bcr-Abl activity in vitro and to induce apoptosis
in CML cell lines as well as in primary CML cells, demonstrating
the potential druggability of this interface.RESULTS
Ile164 Is a Critical Residue for the Integrity of the Active
Conformation of Bcr-Abl
The SH2 domain is thought to act as an intramolecular allosteric
activator of the tyrosine kinase domain in the protooncogenic
kinases Fes and c-Abl (Filippakopoulos et al., 2008, 2009).
Recently, amutation of threonine 231 (Thr231) in the SH2 domain
of the Bcr-Abl protein was identified in imatinib-treated patients
and implicated in causing imatinib resistance (Sherbenou et al.,
2010). The T231Rmutationmay stabilize the SH2-kinase domain
interface by the formation of an additional ionic interaction
with Glu294 in the N lobe of the kinase domain (Figure 1A and
Sherbenou et al., 2010). In contrast, mutation of isoleucine 164
(Ile164), located in the aA-bB-loop of the Abl SH2 domain, to
glutamate (I164E) may nullify the allosteric activation of the Abl
kinase by the SH2 domain by disrupting the SH2-kinase domain
interface (Filippakopoulos et al., 2008; Nagar et al., 2006 and
Figure 1A). These two observations may suggest a possible
role of the Bcr-Abl SH2-kinase domain interface for the activity
of the oncoprotein and even in CML pathobiology.
We introduced the I164E and T231R single mutations and
the I164E/T231R double mutation into Bcr-Abl. Upon expression
in HEK293 cells, global tyrosine phosphorylation, Bcr-Abl
autophosphorylation (on Tyr412 in the activation loop and on
Tyr245 in the SH2-kinase linker), and in vitro tyrosine kinase
activity were reduced in the I164E but increased in the T231R
mutant. The I164E mutation was dominant over the T231R
mutation, consistent with the proposed disrupting effect of
the I164E mutation versus the stabilizing role of the T231Rmuta-
tion (Figures 1B and 1C). In contrast, levels of phosphorylated
Tyr177 in the Bcr part of Bcr-Abl, a site thought to be phosphor-
ylated by Src kinases, were slightly higher in the T231R mutant.
This might suggest higher Src activity in the presence of the
T231R mutation (Figure 1B).
To study the structural role of Ile164 inmore detail, wemutated
Ile164 to different polar/charged amino acids (Glu, Gln, Thr, Asp,
or Lys) or to Ala. All mutations led to a strong reduction of Abl
autophosphorylation and in vitro kinase activity. Somewhat
weaker effects were observed by mutating Ile164 to structurally
related hydrophobic amino acids (Val or Leu) (Figure S1 available
online).
In enzyme-kinetic experiments, the Bcr-Abl I164E mutant
protein displayed a >3-fold reduction in vmax compared to Bcr-
Abl wild-type (WT) and a modest increase in Michaelis-Menten
constant (KM) when assayed in vitro using an optimal Abl sub-
strate peptide containing one single tyrosine (Figure 2A).
Relationship between Phosphotyrosine Binding and
Kinase Domain Binding of the Abl SH2 Domain
SH2 domain-containing tyrosine kinases have been proposed
to use their SH2 domains to bind primed substrates to facilitate
multisite (processive) phosphorylation of substrates with mul-
tiple tyrosine phosphorylation sites (Mayer et al., 1995). Upon
cotransfection of the Bcr-Abl substrate paxillin with Bcr-Abl
I164E, we observed a strong reduction in multisite phosphoryla-
tion of paxillin, whereas the T231R mutation had the opposite
effect (Figures 2B and S1). These data indicate that disruptionCell 147, 306–319, October 14, 2011 ª2011 Elsevier Inc. 307
Figure 1. Structure-Function Analysis of the SH2-Kinase
Domain Interface in Bcr-Abl
(A) Cartoon diagram of the active SH2-kinase domain unit of Abl.
Critical residues involved in the SH2-kinase domain interface that
are discussed in the text are highlighted.
(B) HEK293 cells were transiently transfected with Bcr-Abl WT,
I164E, T231R, or I164E/T231R. Total protein extracts (left panels)
and Abl immunoprecipitates (right panels) were analyzed by
immunoblotting using the indicated antibodies.
(C) Abl immunoprecipitates were assayed for catalytic activity
using an optimal Abl substrate peptide, and total autophosphor-
ylation was quantified. Kinase activity and autophosphorylation of
Bcr-Abl WT were set to 1. The bar graph shows averages ±
standard deviation (SD) from two independent experiments done
in triplicate.
See also Figure S1.
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Figure 2. The SH2-Kinase Domain Interface in Bcr-Abl Is Both Necessary and Sufficient for High Catalytic Activity of the Enzyme
(A) Immunoprecipitated Bcr-Abl WT and I164E proteins were assayed for catalytic activity in the presence of the indicated concentrations of an optimal Abl
substrate peptide containing a single tyrosine phosphorylation site. Averages of three replicates are plotted. The KM and vmax values were calculated after fitting
the data to the Michaelis-Menten equation.
(B) Bcr-Abl WT and I164E constructs were coexpressed with HA-tagged paxillin in HEK293 cells, and total protein extracts were analyzed by immunoblotting
using the indicated antibodies.
(C) The indicated constructs were transiently transfected in HEK293 cells along with HA-paxillin. FRB-FKBP dimerization was induced by treating cells with
AP21967. Total cell lysates were analyzed by immunoblotting using the indicated antibodies.
See also Figure S2.of the SH2-kinase domain interface also influences the cellular
activity of Bcr-Abl.
As the canonical function of the SH2 domain is phosphotyro-
sine binding, we analyzed whether the I164E mutation would
interfere with phosphopeptide-SH2 interactions (Pawson et al.,
2001). Recombinant WT and I164E-mutated Abl SH2 domains
displayed indistinguishable low micromolar binding constants
for an optimal Abl SH2-domain phoshopeptide ligand (Fig-
ure S2). In contrast, Abl SH2 domains bearing the FLVRES
mutants R171L or S173N were unable to bind tyrosine-phos-
phorylated peptides (Figure S2 and data not shown). Togetherthese data show that the I164E mutant does not compromise
phosphotyrosine binding or structural integrity of the SH2
domain. Nonetheless, in the context of full-length Abl kinase,
the I164E mutant was as defective as the FLVRES mutant
S173N in multisite phosphorylation of paxillin (Figure S2). This
shows that aside from the intrinsic reduction in in vitro and
cellular kinase activity, disruption of the SH2-kinase interface
also interferes with multisite phosphorylation of Abl substrates,
even though the phosphotyrosine peptide-binding properties
of the SH2 domain are retained in Abl I164E. In addition, this
indicates that the correct positioning of the SH2 domain mayCell 147, 306–319, October 14, 2011 ª2011 Elsevier Inc. 309
Figure 3. Bcr-Abl I164E Is Not Leukemogenic in a Bcr-Abl Mouse Bone Marrow Transplantation Model
(A) Indicated amounts of primary murine bone marrow cells expressing Bcr-Abl WT, Bcr-Abl I164E, or GFP were seeded in semisolid medium. Cytokine-
independent colonies were scored after 8 days. Error bars represent SD.
(B) Equal amounts of primary murine Lin c-Kit+ Sca-1+ cells expressing Bcr-Abl WT, Bcr-Abl I164E, or GFP were injected in lethally irradiated recipient mice
(n = 4). Overall survival of transplanted mice was monitored over 120 days.
(C) Sections from liver (top panels) and spleen (bottom panels) of representative Bcr-AblWT and I164E transplanted animals were stainedwith hematoxylin/eosin.
(D) Peripheral blood samples were prepared at indicated time points after transplantation and stained with the indicated antibodies and analyzed by FACS.just be as important as the ability of the SH2 domain to bind
primed tyrosine-phosphorylated substrates for further rounds
of phosphorylation.
Induced Tethering of the SH2 Domain to the Kinase
Domain Activates Abl and Depends on Ile164
In order to assess its potential for pharmacological exploitation,
we further investigated the molecular mechanism of the positive
effect of the SH2 domain on kinase activity. We made use of the
FKBP-FRB fusion protein system, in which the SH2 and kinase
domains of Abl are expressed separately but can be induced
to physically associate upon addition of rapamycin (Belshaw
et al., 1996) (Figure 2C). Induced tethering of the Abl SH2 domain
to the Abl kinase domain led to an unexpectedly strong increase
in phosphorylation of cotransfected paxillin and in total cellular
tyrosine phosphorylation (Figure 2C). The effect was reliant on
the presence of both protein components and on the dimeriza-
tion-inducing drug. Importantly, this effect was entirely depen-
dent on the SH2-kinase interface, as mutation of Ile164 abol-
ished the stimulatory effect. This provided conclusive evidence
that docking of the SH2 domain is sufficient for the observed
positive allosteric effect on kinase activity and could thus repre-
sent a targetable interaction.310 Cell 147, 306–319, October 14, 2011 ª2011 Elsevier Inc.The Bcr-Abl SH2-Kinase Interface Is Critical for the
Transformation of Primary Murine Hematopoietic
Cells and Leukemia Formation In Vivo
Wenext determinedwhethermutation of the SH2-kinase domain
interface had an effect on oncogenic transformation and leuke-
mogenicity. Primary murine bone marrow hematopoietic cells
transduced with Bcr-Abl WT were able to form colonies in the
absence of cytokines in semisolid media (Figure 3A). In contrast,
this transforming capability was dramatically reduced in cells
expressing Bcr-Abl I164E (Figure 3A).
We then tested whether this reduction was also manifest in an
in vivo model of Bcr-Abl-induced leukemia (Daley et al., 1990).
Equal numbers of Bcr-Abl WT- and Bcr-Abl I164E-transduced
hematopoietic stem cells were injected into lethally irradiated
recipient mice. Mice transplanted with Bcr-Abl-expressing cells
developed an aggressive myeloproliferative disorder, leading to
death of all animals within 3 weeks (Figure 3B). These mice dis-
played massively infiltrated spleen and liver and loss of normal
organ architecture (Figure 3C). In contrast, all mice transplanted
with Bcr-Abl I164E-expressing cells remained alive for the
120 days of the study (Figure 3B). After this period, no obvious
pathological alterations in the liver or spleen were detected de-
spite confirmation of the presence of Bcr-Abl I164E-transduced
Figure 4. Bcr-Abl I164E Renders Ba/F3 or UT-7 Cell Lines Factor Independent and Differentially Impacts Cellular Signaling Pathways
(A) Expression levels and cellular activity of Bcr-Abl WT and I164E transduced Ba/F3 cells.
(B) Proliferation of Bcr-Abl WT, I164E, or GFP control Ba/F3 cells or UT-7 cells was measured in the presence of the indicated concentrations of IL-3 or GM-CSF.
(C and D) Activation levels of selected components of different cellular signaling pathways by Bcr-Abl WT versus I164E were investigated by immunoblotting of
total lysates from Ba/F3 (B) and U937 cells (C) stably expressing Bcr-Abl WT or Bcr-Abl I164E using the indicated antibodies.
See also Figure S3.cells in all lineages in peripheral blood, bone marrow, and spleen
(Figures 3C and 3D and data not shown). On one hand, this indi-
cates a lack of oncogenic properties of Bcr-Abl I164E that are
necessary to induce a fatal leukemia, but it rules out a possible
defect in engraftment and/or hematopoietic differentiation
caused by the I164E mutation. Together, our results indicate
a crucial role for the SH2-kinase domain interface in Bcr-Abl-
mediated leukemic transformation.
Bcr-Abl I164E Confers Growth-Factor Independence to
Ba/F3 and UT-7 Cells despite Reduced Kinase Activity
To assess cellular effects and downstream signaling of the Bcr-
Abl I164E mutation, we engineered the murine IL-3-dependent
cell line Ba/F3 and the human GM-CSF-dependent cell lineUT-7 to express Bcr-Abl WT and Bcr-Abl I164E. In both cell lines,
we consistently observed higher expression levels of Bcr-Abl
I164E as compared to Bcr-Abl WT, despite equal virus titers
used (Figure 4A and data not shown). Nevertheless, global tyro-
sine phosphorylation was still lower in cells expressing Bcr-Abl
I164E (Figure 4A). Single-cell clone pairs, initially selected for
equal expression levels of Bcr-Abl WT and I164E, quickly
showed increased Bcr-Abl I164E expression within a few
passages (data not shown).
A widely used read-out of Bcr-Abl activity is the ability to
confer cytokine-independent growth to Ba/F3 or UT-7 cells.
Despite the complete lack of leukemogenic activity of Bcr-Abl
I164E (see Figure 3), we observed that Bcr-Abl I164Ewas equally
potent in transforming Ba/F3 or UT-7 cell lines to cytokineCell 147, 306–319, October 14, 2011 ª2011 Elsevier Inc. 311
independence (Figure 4B). A possible explanation is that the
reduced kinase activity of the I164E mutant may be compen-
sated by upregulation of the Bcr-Abl mutant protein levels in
order to allow cytokine-independent proliferation of hematopoi-
etic cell lines.
Analysis of Downstream Signaling Pathways
It is surprising that a single point mutation located outside of
the tyrosine kinase domain and not affecting phosphotyrosine
binding of the SH2 domain could have such a dramatic effect
on the oncogenic activity of Bcr-Abl. Given this crucial function,
we investigated the downstream signaling events that may be
involved. We tested some major phosphorylation events in Ba/
F3 cells, as well as in human U937 cells. As already observed
in HEK293 cells, mutation of Ile164 led to a strong reduction of
global tyrosine phosphorylation and phosphorylation of Tyr412
in the activation loop of Bcr-Abl (Figures 4A and 4D). Important
signaling mediators downstream of Bcr-Abl include the phos-
phorylation and activation of STAT5, Akt, and Erk1/2 (Ren,
2005). We observed a strong reduction in tyrosine phosphoryla-
tion of STAT5 and CrkL in cells expressing Bcr-Abl I164E as
compared to Bcr-Abl WT (Figures 4C, 4D, and S3). As activation
of STAT5 is required for the induction and maintenance of
CML by Bcr-Abl (Nieborowska-Skorska et al., 1999; Hoelbl
et al., 2010), it is tempting to speculate that the inability of Bcr-
Abl I164E to induce CML may mainly be caused by its inability
to activate STAT5.
Surprisingly, despite the strong effect on Bcr-Abl activity, the
I164E mutation had no effect on Erk1/2 and Akt phosphorylation
or other MAPK or PI3K pathway members (Figures 4C and 4D
and data not shown). This is in line with comparable levels of
phosphorylated Tyr177 in Bcr-Abl, which was shown to be crit-
ical for PI3K and MAPK pathway activation (Figure 1B) (Sattler
et al., 2002). Thus, interference with the SH2-kinase domain
interface appears to result in a complex rewiring of the signaling
network with specific downregulated events rather than general
attenuation of signaling, suggesting that uncoupling of the
SH2-kinase module may generate a not only quantitatively but
also qualitatively impaired abnormal Bcr-Abl output. Further-
more, these data are consistent with different thresholds in
Bcr-Abl activity that are required for full signaling output, with
STAT5 activation being a critical event that is highly sensitive
to disruption of the SH2-kinase domain interface.
Disruption of the SH2-Kinase Domain Interface
Sensitizes Bcr-Abl WT and Drug-Resistant
Forms to TKI Inhibition
Pharmacological interference with the SH2-kinase domain inter-
action surface would be particularly attractive if it could alter the
sensitivity of Bcr-Abl to existing TKIs. We tested the sensitivity of
Bcr-Abl I164E toward the CML TKIs imatinib and dasatinib in
in vitro kinase assays (Figures 5A and 5B). Whereas imatinib
and nilotinib exclusively bind Bcr-Abl when its activation loop
is not phosphorylated, binding of dasatinib requires an active
conformation (Schindler et al., 2000; Vajpai et al., 2008). There-
fore, different sensitivities to the two classes have been used
by others and us to monitor different conformational states of
the target enzymes (De Keersmaecker et al., 2008).We observed312 Cell 147, 306–319, October 14, 2011 ª2011 Elsevier Inc.a 4-fold increase in sensitivity of Bcr-Abl I164E for imatinib,
whereas no differences were observed in response to dasatinib
(Figures 5A and 5B). In line with this, the sensitivity of Ba/F3 cells
expressing Bcr-Abl I164E for nilotinib was increased 3-fold
(Figure 5C). We next addressed whether disruption of the SH2-
kinase domain interface also sensitized TKI-resistant mutants
to nilotinib inhibition. Introduction of the I164E mutation in the
imatinib-resistant Bcr-Abl clones H396R or E255K also in-
creased the nilotinib sensitivity of these mutants 3-fold (Fig-
ure 5D and data not shown).
The T315I mutation in Bcr-Abl is the only mutation that is resis-
tant to imatinib, nilotinib, and dasatinib. At concentrations that
only marginally inhibited Bcr-Abl T315I, nilotinib caused a
dramatic reduction in the in vitro tyrosine kinase activity in the
Bcr-Abl T315I/I164E double mutant (Figure 5E). Finally, the
I164E mutation also increased the sensitivity of Bcr-Abl T315I-
expressing Ba/F3 cells toward the allosteric myristate-binding
pocket inhibitor GNF-2 (Zhang et al., 2010 and Figure 5F). These
results extend the recently proposed cooperativity between the
myristate pocket and the ATP-binding site (Zhang et al., 2010) to
the SH2-kinase domain interface and indicate that disruption of
the SH2-kinase domain interface not only sensitizes Bcr-Abl WT
to imatinib/nilotinib but could also be used to enhance inhibition
of TKI-resistant Bcr-Abl mutants.
Targeting of the Bcr-Abl SH2-Kinase Interface
using Monobodies
To test whether the SH2-kinase interface can be targeted using
an inhibitor in trans, we generated single-domain binding pro-
teins based on the fibronectin type III domain (FN3), termed
monobodies, that target the Abl SH2 domain (Koide and Koide,
2007; Wojcik et al., 2010). We have previously described the
Abl SH2-binding monobody HA4, which acts as a competitive
inhibitor of phosphotyrosine binding (Wojcik et al., 2010). Using
HA4 as a competitor in phage-disply library sorting, we identified
an Abl SH2monobody, designated 7c12, that bound to a distinct
site. 7c12 binds the Abl SH2 domain with a dissociation constant
(KD) of 50 nM (Figure S4 and data not shown). In in vitro kinase
assays, 7c12 inhibited kinase activity of Bcr-Abl WT and T315I,
but not of Bcr-Abl I164E or Bcr-Abl T315I/I164E (Figures 6A
and S4). Although the effect was mild, it was statistically signifi-
cant and did not occur with a recombinant control protein, which
does not bind the Abl SH2 domain. This suggested a possible
involvement of the Bcr-Abl SH2-kinase domain interface in
7c12 binding. In fact, the I164E mutation reduced binding of
7c12 by a factor of 400 (Figure 6B).
Crystal Structure of the Abl SH2 Domain-7c12
Monobody Complex
To elucidate the molecular details of the 7c12-Abl SH2 interac-
tion, we determined the crystal structure of the complex at
2.1 A˚ resolution (PDB ID: 3T04; Table S1; Figures 6C and S5).
The asymmetric unit consists of a single monobody-SH2 domain
complex (Figures 6C and S5A). The 7c12 monobody and the Abl
SH2 domain contribute nearly equally to the1340 A˚2 of surface
area buried in the complex. The diversified loops contribute
nearly 75% of the binding interface with each of the three loops
making substantial contributions (91, 178, and 234 A˚2 for the BC,
Figure 5. Bcr-Abl I164E Sensitized WT and Imatinib-Resistant Bcr-Abl Forms to TKI Inhibition
(A, B, D, and E) Kinase activity of the indicated immunoprecipitated Bcr-Abl constructs was assayed in the presence of the indicated concentrations of imatinib
(A), dasatinib (B), or nilotinib (D and E). For each dataset, the activities of the untreated samples were set to 1. Each data point in the graphs represents the
averages ± SD from two independent experiments done in duplicate.
(C and F) Viability of Ba/F3 cells expressing Bcr-Abl WT, I164E, T315I, and T315I/I164E was measured in the presence of the indicated concentrations of nilotinib
(C) or GNF-2 (F) and normalized to 1 for each dataset. For all panels, significance levels are indicated (ns: not significant, *p < 0.05, **p < 0.01, ***p < 0.001). Each
data point in the graphs represents the averages ± SD from one representative experiment done in sextuplicate.DE, and FG loops, respectively). The D strand of the monobody
scaffold also makes substantial contribution to the interface. It
packs against the C-terminal tail of the SH2 domain through an
intermolecular b sheet (Figure S5A, red box and S5B). Outside
of these backbone-mediated interactions, the interface is domi-
nated by hydrophobic contacts between monobody loop resi-
dues and two surface concavities on either side of b strand B
of the SH2 domain. At the end of the monobody D strand, the
DE loop forms a hairpin that packs against one of these concave
surfaces that is formed by the bB strand and the aA helix of
the Abl SH2 domain (Figure S5C). Pro60 and Tyr62 make most
of the DE loop contacts, together burying more than 150 A˚2 of
surface area.
The second surface concavity is bounded on one side by
b strand B of the Abl SH2 domain, on the other by a helix B,
and from above and below by the N-terminal and C-terminal tails
of the Abl SH2 domain (Figure S5A, cyan box). Phe87 of the 7c12
FG loop penetrates deep into the center of this pocket, burying
133 A˚2 of surface area on its own. Other residues in the FG loop
(Phe88, Pro89), Val38, and the aliphatic portion of Lys39 of the
BC loop form a ring of hydrophobic contacts at the periphery ofthis surface pocket (Figure S5D). Together, these residues con-
tribute nearly 300 A˚2 to total monobody surface area burial.
The interfaceobserved in thecrystal structure is alsoconsistent
with the strong negative effect of the I164E mutant on 7c12-SH2
interaction (Figure 5B). Ile164 is located at the edge of the 7c12-
binding interface andcontributes 29 A˚2 of surface to the interface.
It makes hydrophobic interactions with Tyr62 of the DE loop (Fig-
ure S5C). These features rationalize the 400-fold reduction in
binding affinity by the I164E mutation (Figure 6B).
In order to further confirm the authenticity of the interaction
interface observed in the crystal structure, we used nuclear
magnetic resonance (NMR) spectroscopy to conduct epitope
mapping. The Abl SH2 backbone amide resonances most
greatly affected by the presence of 7c12, as measured in 15N
HSQC experiments, are in good agreement with portions of
the SH2 domain that are contacted by 7c12 in the crystal struc-
ture (Figure S5F), suggesting that the interface observed in the
crystal structure corresponds to the actual solution-phase
interaction. To further validate the crystal structure using an
independent experimental approach, we mutated each of the
loop regions individually back to the template sequence andCell 147, 306–319, October 14, 2011 ª2011 Elsevier Inc. 313
Figure 6. Targeting the SH2-Kinase Domain Interface with the Engineered Monobody Protein 7c12 Leads to Bcr-Abl Inhibition
(A) In vitro kinase activity of immunoprecipitated Bcr-Abl WT, I164E, T315I, and T315I/I164E proteins was assayed in the presence of the indicated concentrations
of recombinant 7c12. FKBP12 was used as a control recombinant protein. Activity of each Bcr-Abl mutant-buffer control was normalized to 1. Significance levels
are indicated (ns: not significant, *p < 0.05, **p < 0.01, ***p < 0.001). The bar graph shows averages ± SD from at least three independent experiments done
in triplicate. See also Figure S4.
(B) Competition phage ELISA of the 7c12monobody. Phages displaying the 7c12monobody were bound to GST-Abl SH2WT or I164E protein. Unbound phages
were exposed to immobilized Abl SH2 domain and detected using an anti-phage antibody. Values are normalized to the intensity of the ELISA signal in the
absence of a competitor.
(C) Crystal structure of the complex of the monobody 7c12-Abl SH2 domain complex (PDB entry 3T04). Ile164 is part of the interface and shown in red. Lower
panel: Superposition of the 7c12-Abl SH2 complex and the active Abl structure. The surface of the Abl kinase domain is shown to highlight the incompatibility of
simultaneous binding of 7c12 and the Abl kinase domain to the SH2 domain. See Table S1 and Figure S5 for details.
(D) Superposition of the 7c12-Abl SH2 domain complex (PDB entry 3T04) and the HA4-Abl SH2 complex (PDB entry 3K2M) crystal structures. HA4 and 7c12 are
shown in blue and orange, respectively. The Gly-Ser linker between HA4 and 7c12 is indicated as a dotted red line. Arg171 in the Abl SH2 domain is shown to
indicate the location of the phosphotyrosine-binding pocket. Residues Tyr88, Tyr172, and Phe197 were mutated to abolish binding to the Abl SH2 domain. See
also Figure S5.
(E) In vitro kinase activity of immunoprecipitated Bcr-AblWT protein was assayed in the presence of the indicated concentrations of recombinant HA4-7c12WT or
the nonbinding Y88A/Y172E/F197K mutant protein. Significance levels are indicated (ns: not significant, *p < 0.05, **p < 0.01, ***p < 0.001). The bar graph shows
averages ± SD from one representative experiment done in triplicate. See also Figure S6.
314 Cell 147, 306–319, October 14, 2011 ª2011 Elsevier Inc.
measured the binding affinity of these mutants. In each case, the
mutant-Abl SH2 domain interaction was at least 100 times
weaker than the wild-type 7c12-Abl SH2 interaction (data not
shown). These results are consistent with the crystal structure,
in which each loop makes a significant contribution to the
7c12-Abl SH2 interaction. Together, these studies provide
significant validation of the observed crystal structure interface.
Comparison of the 7c12-Abl SH2 Interface to the Abl
SH2-Kinase Domain Interface
We next compared the Abl SH2-kinase domain interface with
the 7c12-Abl SH2 interface (Figures 6C and S5). The size of
the SH2-kinase domain interface is 1030 A˚2, 75% of that
of the 7c12-Abl SH2 interface. More than half of the total surface
area of the SH2-kinase interface overlaps with the 7c12-SH2
domain interface centered on b strand B of the Abl SH2 domain
(Figures S5G and S5H). This significant overlap in the 7c12-Abl
SH2 and Abl SH2-kinase interfaces strongly suggests that the
binding of the SH2 domain to the kinase domain and to 7c12
are mutually exclusive (Figures 6C, S5G, and S5H). The incom-
patibility of simultaneous binding of the SH2 to both the kinase
domain and 7c12, therefore, likely explains the observed inhibi-
tion of Bcr-Abl kinase activity, as full 7c12 binding requires
the disruption of the SH2-kinase domain interface. Given the
theoretical difficulty of competing intermolecularly with an
1100 A˚2 intramolecular protein-protein interaction and the
partial occlusion of the 7c12-binding site on the SH2 domain
by the kinase domain, we consider the degree of inhibition that
is achieved by the 7c12 monobody to be symptomatic and
strongly indicative of a specific vulnerability.
Improved Targeting of the SH2 Interface with a Tandem
Fusion of the HA4 and 7c12 Monobodies
Despite the clear demonstration of the general feasibility of
targeting the SH2-kinase interface using 7c12, we aimed at
improving its biological potency. Superposition of the structure
of the previously characterized HA4 monobody bound to the
Abl SH2domain (Wojcik et al., 2010)with the 7c12-Abl SH2 struc-
ture reveals that the two monobodies bind on opposite faces of
the SH2 domain with no overlap (Figures 6D and S5E). This
arrangement is consistent with the selection scheme employed
for the generation of 7c12, in which HA4 was used as a compet-
itor, and with sandwich-ELISA data indicating that HA4 and 7c12
can bind simultaneously to the same Abl SH2 domain molecule
(data not shown). HA4 binds with low nanomolar affinity to the
phosphotyrosine-binding pocket of the Abl SH2 domain, which
is not part of an intramolecular interaction in Bcr-Abl and is
able to effectively outcompete phosphotyrosine ligand binding
(Wojcik et al., 2010). For these reasons, we attempted to link
HA4 and 7c12 in tandem, which should increase the local
concentration of 7c12 in proximity to the SH2-kinase domain
interface and further enhance the specificity toward the Abl
SH2 domain. A 19 amino acid Gly-Ser linker was used to bridge
the C terminus of HA4 to the N terminus of 7c12, based on struc-
tural modeling (Figure 6D). As negative controls, we introduced
point mutations in both parts of the HA4-7c12 tandem mono-
body. For HA4,we used the Y88A (Y87A in the original numbering
scheme) mutation that was previously shown to reduce bindingto the Abl SH2 domain >1000-fold (Wojcik et al., 2010). We also
designed a double point mutation (Y172E/F179K; Y62E/F87K in
the original numbering scheme, Figure S5) for the 7c12 part,
which is located at structurally central positions of the 7c12-Abl
SH2 interface and showed a strong reduction in binding in pull-
down experiments (data not shown). We tested the HA4-7c12
tandem monobody in Bcr-Abl in vitro kinase assays. We
observed a strong inhibition of Bcr-Abl activity with low micro-
molar concentrations of the HA4-7c12 tandem monobody,
whereas the nonbinding Y88A/Y172E/F179K mutant failed to
inhibit Bcr-Abl activity (Figure 6E). Importantly, the degree of inhi-
bition of Bcr-Abl activity achieved by HA4-7c12 was comparable
to that upon introduction of the I164Emutant (Figures 1Cand2A).
HA4-7c12 was also able to inhibit Bcr-Abl T231R, although to
a lesser degree than Bcr-Abl WT (Figure S6). This indicates that
the tandem monobody may lead to a complete disruption of
the Bcr-Abl kinase domain interface.The HA4-7c12 Tandem Monobody Strongly Inhibits
Cellular Bcr-Abl Activity and Induces Apoptosis
in CML Cells
Finally, we tested whether the HA4-7c12 tandem monobody
would also inhibit Bcr-Abl activity in CML cells. Transient expres-
sion of a HA4-7c12-GFP fusion protein in the Bcr-Abl-positive
CML cell line K562 led to a strong reduction of activation loop
(Tyr412) phosphorylation of Bcr-Abl (Figure 7A). This effect
was dependent on both HA4 and 7c12 moieties of the tandem
monobody, as expression of point mutants that abolish binding
of either HA4 (Y88A) or 7c12 (Y172E/F197K) or both to the Abl
SH2 domain did not show this effect (Figure 7A).
We next tested whether the HA4-7c12-induced decrease in
Bcr-Abl activity with HA4-7c12would result in cell death. Indeed,
K562 cells expressing the HA4-7c12 tandemmonobody showed
high amounts of apoptosis, as measured by TUNEL and cleaved
caspase 3 staining (Figures 7B and S7A). Again, this effect was
not evident when the nonbinding mutant was used.
Next, we asked whether HA4-7c12 would inhibit Bcr-Abl-
induced transformation of primary murine bone marrow cells.
In contrast to the nonbinding mutants, bicistronic expression
of Bcr-Abl and GFP-HA4-7c12 WT severely impaired cytokine-
independent colony formation in semisolid media (Figure 7C).
Finally, we tested whether HA4-7c12 would induce apoptosis
in primary bone marrow or peripheral blood cells from CML
patients at different stages of the disease (Table S2). Lentiviral
expression of HA4-7c12 induced an65% increase in apoptotic
cells over the nonbinding mutant HA4 Y88A-7c12-Y172E/F197K
in cells from patients in chronic phase (Figure 7D, left panel). This
increase was comparable to the induction of apoptosis upon
treatment of the same cultures with 2 mM nilotinib for 5 days
(41%). Similar results were obtained when cells from patients in
the accelerated phase of the disease were used (Figure 7D, right
panel). Here, nilotinib treatment led to a 40% increase whereas
expression of HA4-7c12 induced a 49% increase in apoptosis.
Together, these data show that Bcr-Abl activity can be in-
hibited by targeting the SH2-kinase interface using FN3-based
monobodies in CML cell lines, as well as in primary cells from
CML patients.Cell 147, 306–319, October 14, 2011 ª2011 Elsevier Inc. 315
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DISCUSSION
In this study, we have identified the SH2-kinase domain interface
as a critical structural feature that is important for the adoption
and maintenance of the active conformation of Bcr-Abl. We
show that disruption of this interface completely abolishes
Bcr-Abl leukemogenicity. Therefore, the SH2-kinase domain
interface in Bcr-Abl represents an attractive ‘‘druggable’’ target
in addition to its ATP- andmyristate-binding sites. As amolecular
tool, we developed the FN3-based monobody 7c12 and the
tandem monobody HA4-7c12 that showed strong inhibition of
Bcr-Abl activity in vitro and induced apoptosis in CML cells.
The HA4-7c12 fusion is an example of the use of two FN3mono-
bodies in tandem to achieve a higher level of target inhibition.
Although we show that lentiviral delivery of the HA4-7c12
cDNA was able to induce apoptosis in primary cells from CML
patients, difficulties with intracellular delivery of the HA4-7c12
protein will most probably limit or preclude the use of monobod-
ies as drug-like molecules in clinical applications. In contrast, the
exquisite affinity and specificity of HA4-7c12 for Bcr-Abl suggest
general utility of monobodies as target validation tools for
preclinical studies.
Recent data confirmed evidence for a positive role of the SH2
domain on the adjacent tyrosine kinase domain in selected cyto-
plasmic tyrosine kinases (Filippakopoulos et al., 2008; Mikkola
and Gahmberg, 2010; Joseph et al., 2007), originally identified
in the v-Fps/Fes oncoprotein (Sadowski et al., 1986). Despite
this conserved allosteric regulatory property of the SH2 domain,
the surfaces involved in establishing the interface between
the SH2 domain and the tyrosine kinase domain N lobe appear
to be diverse in terms of biophysical properties, size, and affinity
amongdifferent tyrosine kinases. Theunderlying structuralmech-
anismresponsible for theactivationof theAbl kinasedomainby its
SH2 domain is still elusive and should be the subject of an inde-
pendent study. However, the I164E mutation disrupts the SH2-
kinase domain interface while leaving the core function of the
SH2 domain—binding of phosphotyrosine ligands—unaffected.
Previous studies have attempted to address the role of the SH2
domain for oncogenic transformation and leukemogenicity of
Bcr-Abl either bymutating the conserved Arg171 in the phospho-
tyrosine-binding pocket or by deleting the entire domain (Ilaria
and Van Etten, 1995; Roumiantsev et al., 2001). However, theFigure 7. The Tandem Monobody HA4-7c12 Strongly Inhibits Cellular B
Primary Cells
(A) K562 cells were transiently transfected with the indicated HA4-7c12-GFP fus
cytometry. Left panel: Histograms of Bcr-Abl pY412 fluorescence intensities of th
panel: Quantitation of Bcr-Abl pY412 fluorescence. The intensities were normaliz
Figure S5) and cells transfected with the nonbinding mutant HA4 Y88A-7c12 Y1
(B) K562 cells treated as described in (C) were analyzed for apoptosis using TUNE
fraction of cells transfected with the indicated constructs. Right panel: Quantitatio
treated with nilotinib (arbitrarily set to 100%; Figure S7C) and mock-transfected
(C) Primary murine bone marrow cells were transduced with the indicated retr
cytokine-independent colonies were scored.
(D) Primary cells fromCML patients from chronic phase (left panel) or accelerated p
HA4 Y88A-7c12 Y172E/F197K. Parallel cultures from the same patients were trea
caspase staining by FACS. Levels of apoptosis in the GFP-positive fraction of c
normalized to 1. p values: Chronic phase (five patients): 0.0007; accelerated pha
In all panels, error bars represent SD. See Table S2 and Figure S7 for details.widely used mutation of Arg171 is associated with a loss of the
integrity of the SH2 domain (Figure S1 and data not shown).
Therefore, as in the case of deletion of the entire domain, both
the phosphotyrosine-binding function as well as themaintenance
of the SH2-kinase domain interface are likely to be compromised
upon introduction of the Arg171 mutation. Thus, the observed
effects on transformation and leukemogenicity likely reflect
a combination of multiple effects caused by interference with
the protein architecture.
As interference with the SH2-kinase domain interface leads
to a dramatic reduction in Bcr-Abl activity, one would expect
a uniform decrease in the activation of the major pathways that
are activated by Bcr-Abl. Instead, we observed an almost exclu-
sive loss of STAT5 activation. STAT5 is a central component that
is required for the induction andmaintenance of CML induced by
Bcr-Abl (Nieborowska-Skorska et al., 1999; Hoelbl et al., 2010).
Therefore, it is tempting to speculate that the inability of Bcr-Abl
I164E to induce CML is caused by its inability to activate STAT5.
It has been shown that even short-term blockage of Bcr-Abl
action resulted in severe and complete inhibition of STAT5
activity and target gene expression (Shah et al., 2008; Hantschel
et al., 2008). In contrast, other pathways, including the Ras-
MAPK or the PI3K-Akt pathways, were not compromised
strongly. This may be the reason that Bcr-Abl I164E, although
not leukemogenic, may confer cytokine independence to Ba/
F3 or UT-7 cells.
Together, our work shows that interfering with the SH2-kinase
domain interface can allosterically inhibit Bcr-Abl activity. It
should be feasible to develop a small molecule that interferes
with this SH2-kinase domain interaction. Such allosteric mod-
ulators could be of either antagonistic or agonistic nature de-
pending on the targeted surface and binding mode. This may
represent an attractive option for patients with chronic phase
CML that only achieve a suboptimal response or are resistant
to TKI therapy, as well as for patients with advanced stage
CML or Ph-positive acute lymphoblastic leukemia.EXPERIMENTAL PROCEDURES
Cells
Cell lines or primary cells were transduced with the indicated constructs
using pMSCV-IRES-GFP-based retroviral vectors for 72 hr in the presencecr-Abl Kinase Activity and Induces Apoptosis in CML Cell Lines and
ion constructs, and Bcr-Abl Tyr412 phosphorylation was measured using flow
e GFP-positive fraction of cells transfected with the indicated constructs. Right
ed to K562 cells treated with nilotinib (complete inhibition—arbitrarily set to 0;
72E/F197K (no inhibition—arbitrarily set to 1) (n = 3).
L staining. Left panel: Histograms of TUNEL fluorescence of the GFP-positive
n of TUNEL-positive cells (n = 3). The intensities were normalized to K562 cells
cells (arbitrarily set to 0%) (n = 3).
oviral constructs. GFP-positive cells were seeded in semisolid medium, and
hase (right panel) were transducedwith lentiviruses encodingHA4-7c12WT or
ted with nilotinib for 5 days. Apoptosis was measured after 5 days via cleaved
ells transduced with HA4 Y88A-7c12 Y172E/F197K or in untreated cells were
se (two patients): 0.011; one-way ANOVA).
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of IL-3, IL-6, SCF, and 7 mg/ml polybrene. For transient monobody expression,
1 3 106 K562 cells were transfected with 5 mg of expression vectors encod-
ing GFP fusion constructs of HA4-7c12 and mutants thereof using the Nucle-
ofector Kit V (Amaxa), applying program T-016. Samples were harvested 48 hr
later. Primary CML cells were isolated from bone marrow or peripheral blood
samples of patients with Ph-chromosome-positive CML at time of diagnosis.
All patients gave written informed consent before blood or bone marrow
was obtained. Cells were transducedwith concentrated lentiviral supernatants
via spinoculation (10003 g, 90 min) at a multiplicity of infection (moi) of 20 and
cultivated in RPMI 1640 medium plus 10% FCS and 100 ng/ml human Inter-
leukin 3 (PeproTech). The study was approved by the Institutional Review
Board (IRB) of the Medical University of Vienna.
Primary Cell Transformation Assay and Bone Marrow
Transplantation
GFP-positive cells were isolated using fluorescence-activated cell sorting
(FACS) and seeded in cytokine-freemethylcellulose, and colonies were scored
8 days later. For bone marrow transplantation studies, transduced cells were
injected into lethally irradiated (10 Gy) WT recipients via the tail vein. Peripheral
blood samples of animals were regularly scored for the presence of GFP-Bcr-
Abl-positive cells. Upon signs of sickness, mice were sacrificed and hemato-
poietic organs were analyzed for leukemic cells by FACS using fluorescently
labeled antibodies against GR-1, Mac-1, CD19, and CD3. Tissues were fixed
in paraformaldehyde prior to sectioning and staining with hematoxylin/eosin.
Kinase Assays
Immunoprecipitation of Bcr-Abl/c-Abl protein and Abl in vitro kinase assay
were carried out as described previously (Hantschel et al., 2003). Immuno-
precipitated Bcr-Abl proteins were resuspended in kinase assay buffer
containing the indicated concentrations of tyrosine kinase inhibitor or re-
combinant monobody protein. A peptide with the preferred Abl substrate
sequence carrying an N-terminal biotin (biotin-GGEAIYAAPFKK-amide)
was used as substrate. The terminated reaction was spotted onto a SAM2
Biotin Capture membrane (Promega) and further treated according to the
instructions of the manufacturer. The relative amount of immunoprecipitated
Abl protein was determined by immunoblotting and subsequent relative
quantification using the Li-Cor Odyssey system.
Induced Tethering of the Abl SH2 Domain to the Abl Kinase Domain
For the experiments described in Figure 2C, we used the Regulated Heterodi-
merization Kit from Ariad Inc. FRB was fused to the N terminus of the SH2
domain and FKBP12 to the N terminus of the kinase domain and transiently
transfected in HEK293 cells along with HA-Paxillin. Forty-eight hours after
transfection, we induced dimerization of FRB-SH2 domains with FKBP-kinase
domain constructs by treating cells with 2 mM of AP21967 for 3 hr.
Monobody Selection and Preparation
To identify monbobodies to the kinase-interaction surface of the Abl SH2
domain, a phage-display library was sorted using biotinylated Abl SH2 as
a target in the presence of a 5-fold excess of the monobody HA4, which
binds to the phosphopeptide interface of the SH2 domain (Wojcik et al.,
2010). Otherwise, selection, cloning, and expression of the 7c12 monobody
were carried out as described previously (Koide and Koide, 2007, Wojcik
et al., 2010). Proteins were produced with an N-terminal His10-tag and purified
using a Ni–Sepharose column (GE Lifesciences) to apparent homogeneity.
The His-tag moiety was removed by protease cleavage prior to crystallization.
For the HA4-7c12 tandem monobody, the sequences of HA4 and 7c12 were
linked by a (Gly-Ser)-linker.
Intracellular Flow Cytometry
Cells were fixed in 3.2% paraformaldehyde and stored in Methanol, followed
by staining with antibodies recognizing Stat5 phosphorylated on Tyr697 (BD
Biosciences), CrkL phosphorylated on Tyr207 (Cell Signaling), or Abl phos-
phorylated on Tyr412 (Cell Signaling) followed by a PE-conjugated goat
anti-rabbit secondary antibody (Imgenex). For analysis of apoptosis, cells
were stained with antibodies against cleaved caspase 3 (Cell Signaling) or318 Cell 147, 306–319, October 14, 2011 ª2011 Elsevier Inc.subjected to TUNEL followed by staining with a PE-conjugated anti-BrdU
antibody according to the manufacturer’s instructions (BioVision).SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures, seven
figures, and two tables and can be found with this article online at doi:10.1016/
j.cell.2011.08.046.
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